¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ±Û¾²±â ¼öÁ¤ »èÁ¦

ÀÎõ¼ÒÈ­ºÒ·® ´ãÀûº´ Ä¡·á °ÆÁ¤³¡

ÃßõÇϱâ
ÇÑÀÇ¿ø À̹øÁÖ BEST
 
#ÀÎõ¼ÒÈ­ºÒ·®, #ÀÎõ¼ÒÈ­ºÒ·®Ä¡·á, #´ãÀûº´, #ÀÎõ´ãÀûº´, #¼ÒÈ­ºÒ·®Ä¡·á, #´ãÀûº´Ä¡·á, #ÀÎõ´ãÀûº´, #ºÎõ¼ÒÈ­ºÒ·® ÀÎõ¼ÒÈ­ºÒ·®,,ÀÎõ¼ÒÈ­ºÒ·®Ä¡·á,,´ãÀûº´,,ÀÎõ´ãÀûº´,,¼ÒÈ­ºÒ·®Ä¡·á,,´ãÀûº´Ä¡·á,,ÀÎõ´ãÀûº´,,ºÎõ¼ÒÈ­ºÒ·® ¾È³çÇϼ¼¿ä. ÀÎõ¼ÒÈ­ºÒ·® ºÎõ ÇÑÀÇ¿ø ãÀ¸½Ã´Â ºÐµéÀÌ ¸¹À¸½Åµ¥¿ä ÀÎõ¼ÒÈ­ºÒ·® ºÎõ Ä¡·á ãÀ¸½Ã´Â ºÐµéÀÌ ¹Ì¿ÃÇÑÀÇ¿ø ÀÎõÁ¡À» ÀÚÁÖ Ã£À¸½Ã´Âµ¥¿ä. ¹Ì¿ÃÇÑÀÇ¿ø¿¡´Â´ãÀûº´, ´ãÀûÁõ, ´ãÀûº´ÇÑÀÇ¿ø, ±Þ¼ºÀå¿°, Ç÷º¯, Àå³»°¡½ºÁ¦°Å, ½Å°æ¼ºÀ§¿°, º¹ºÎ°¡½º, ½Ä¿åºÎÁø, ½Äµµ¿°, À§°æ·Ã, ¸¸¼º¼³»ç, Å©·Ðº´, À§´ãÀû, ÀæÀºÆ®¸², ´ãÀûÁõ»ó, ¸¸¼ºÀ§¿°, À§¿°¸íÄ¡, ¼Ó¿ï··°Å¸², ¸íÄ¡¾²¸², ¼ÒÈ­ºÒ·®, ¼ÒÈ­ºÒ·®Áö¼Ó, ÀæÀº¹èº¯, À§¼Ó¾²¸², À§ÀåÀå¾Öµî ´Ù¾çÇÑ ¹®ÀǸ¦ ÁÖ°í °è½Ê´Ï´Ù. ¹Ì¿ÃÇÑÀÇ¿ø¿¡´Â ´Ù¾çÇÑ È¯ÀںеéÀÌ ³»¿øÇÏ°í °è½Ã¸ç °³Àκ° Áõ»ó°ú üÁú¿¡ µû¶ó °æÃßÃß³ª, Áß¼º¾îÇ÷¾àħ, mechanical therapy, ³úÇ÷·ùÃÊÀ½ÆÄ, ÁÂÈÆ¿ä¹ý, ½½¸µ¿îµ¿, ôÃß°ßÀÎÄ¡·á, ³Ã¿Â¿å, ü¿­Áø´Ü(ºÎºÐ), °æÇÇ°æ±ÙÇѳÿä¹ý, Àδ밭ȭ, ¾ÆÀ̽ºÆÑ, Çѹ湰¸®Ä¡·á, ¿äõÃßÃß³ª, ¹Ì¼¼¾àÃÊÀڱؿä¹ý, ÈûÁÙ°­È­Ä¡·á, ¾È¸é°èÃø°Ë»ç, »ê»ï¾àħ, ½Å¹Ù·Î¾àħ, ·¹ÀÌÀú, ¸ÂÃãÇÑ¾à µî ÇÕ¸®ÀûÀÌ°í È¿°úÀûÀÎ ¸ÂÃã Ä¡·á¸¦ Á¦°øÇÏ°í ÀÖ½À´Ï´Ù ¹Ì¿ÃÇÑÀÇ¿øÀº Àü±¹ 20¿©°³ ÁöÁ¡¿¡¼­ Áø·áÁßÀ̸ç ÀüºÏ Á¤À¾½Ã ³ó¼Òµ¿, Á¦ÁÖ ¼­±ÍÆ÷½Ã µ¿È«µ¿, °æ±â È­¼º½Ã Ȳ°èµ¿, ÀüºÏ Àå¼ö±º °èºÏ¸é, Àü³² °î¼º±º ¿À°î¸é, ¿ï»ê ¿ïÁÖ±º û·®¸é, ºÎ»ê ±ÝÁ¤±¸ ºÎ°îµ¿, Àü³² ¿µ¾Ï±º »ïÈ£À¾, ÃæºÏ ¿Áõ±º ¿ÁõÀ¾, ¿ï»ê ³²±¸ °³¿îµ¿, Àü³² ¿µ±¤±º ´ë¸¶¸é, °æ³² â¿ø½Ã ¸¶»êÇÕÆ÷±¸ ¸¶»êÇÕÆ÷¿ìü±¹»ç¼­ÇÔ, °­¿ø °í¼º±º °ÅÁøÀ¾, ÀüºÏ ¿ÏÁÖ±º ¿îÁÖ¸é, ÀüºÏ ÀüÁֽà ´öÁø±¸ ¿ì¾Æµ¿2°¡, °­¿ø Ãáõ½Ã ÈÄÆòµ¿, °æ±â ¾È¾ç½Ã ¸¸¾È±¸ ¼®¼ö2µ¿, Ãæ³² ±Ý»ê±º ±Ý»êÀ¾, °æ³² â¿ø½Ã ¼º»ê±¸ ¿ù¸²µ¿, °æ±â ¿ëÀνà ±âÈﱸ û´öµ¿, °æºÏ »óÁֽà ȭ°³µ¿, ºÎ»ê ¼ö¿µ±¸ ±¤¾Èµ¿, ÀüºÏ ±º»ê½Ã ¹ÌÀ嵿, °­¿ø Æòⱺ ¹æ¸²¸é, °æ±â µ¿µÎõ½Ã »ý¿¬2µ¿, Àü³² °î¼º±º °î¼ºÀ¾, °æºÏ »óÁֽà ³»¼­¸é, ºÎ»ê °­¼­±¸ ¹ü¹æµ¿, °æ±â ½ÃÈï½Ã Á¤¿Õ2µ¿, °æ±â ½ÃÈï½Ã Á¤¿Õ2µ¿, µî ´Ù¾çÇÑ Áö¿ª Áֹε鲲¼­ ³»¿øÇÏ°í °è½Ê´Ï´Ù ÀÎõ¼ÒÈ­ºÒ·®Ä¡·á ãÀ¸½Ã´Â µ¿Ãᵿ, ¼®³²µ¿, ¼Ò·¡Æ÷±¸, ¿ëÇöµ¿, ¹è°ð½Åµµ½Ã, ÀÎõ³íÇöµ¿, ½ÃÈï, Á־ȵ¿, ¿¬¼öµ¿, ¿Á·Ãµ¿, À²¸ñµ¿, ¼±Çе¿, ³²¾çÀ¾, ÀÎõ, ±¸¿ùµ¿, ¿î¼­µ¿, °£¼®µ¿, ´ëºÎµµ, ³íÇö°íÀܵ¿, Á¤¿Õµ¿, ¹è°ð, °è»êµ¿, ¼­Ã¢µ¿, ¼Û¸²µ¿, ¼Ûµµ, °Ë¾Ï, °ü±³µ¿, ÀÎõÁÖ¾È, ¼Ûµµ½Åµµ½Ã, ½ÃÈ­, ¼Û»ê¸é, ³²±¸, °è¾ç±¸, Áßµ¿, ¸¶µµ¸é µî ÀÎõ Áö¿ª Áֹε鲲¼­ ¹Ì¿ÃÇÑÀÇ¿øÀÎõÁ¡À» ¹æ¹®ÇÏ°í °è½Ê´Ï´Ù. ´õ »ìÆ캸±â 1. Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14:1595. 2. Janiak P, Thumshirn M, Menne D, et al. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial. Aliment Pharmacol Ther 2007; 26:1259. 3. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995; 40:86. 4. Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7:175. 5. Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2012; 107:1662. 6. Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007; 26:1333. 7. Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008; 6:521. 8. Wedlake L, A'Hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009; 30:707. 9. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15:355. 10. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006; 23:1473.
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ÀÎõ¼ÒÈ­ºÒ·® ´ãÀûº´ Ä¡·á °ÆÁ¤³¡""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ±Û¾²±â ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ÀÎõ¹«¿ù°æ Ä¡·á ÁÖ¸»Áø·á
´ÙÀ½±Û ÀÎõÀ¯»êÈÄÇѾà ÇÑÀÇ¿ø °ÆÁ¤¸»°í
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
952 ´ÙÀ̾îÆ®ÇÑÀÇ¿ø »õÇØ À̺¥Æ® ÁøÇà ´ÙÀ̾îÆ®ÇÑ¾à ±¸ÀÔ Æ÷ÀÎÆ® Á¦°ø 0 111 2024-01-15
951 ÀÌõ±³Åë»ç°íÇÑÀÇ¿ø Ãʱ⠰ü¸®·Î ÈÄÀ¯Áõ ¿¹¹æÇØ¿ä 3 331 2023-10-14
950 ÆíµÎÅë ¿¹¹æ¾à ó¹æ, ÁøÅëÁ¦¿Í ÇѾà Ä¡·á ¾Ë¾Æº¸±â 0 334 2023-10-13
949 ¸Þ´Ï¿¡¸£º´ Áø´Ü ¹Þ¾Ò´Ù¸é ¾çÀç µÎûÇÑÀÇ¿øÀ¸·Î 0 360 2023-10-13
948 »êº»±³Åë»ç°íÇÑÀÇ¿ø Ä¡·á¸¸Á·µµ ³ôÀº ÀÌÀ¯ 0 535 2023-08-18
947 â¿ø ÇѾàÀßÁþ´Â°÷ À¯¾Ø¹ÌÇÑÀÇ¿ø 2 820 2023-06-02
946 [ÆíµÎÅëÄ®·³2ź]µÎûÇÑÀÇ¿ø, ÆíµÎÅëÀÌ Ä¡·á°¡ ¾ÈµÇ´Â ÀÌÀ¯ 0 647 2023-05-23
945 [ÆíµÎÅëÄ®·³1ź]µÎûÇÑÀÇ¿ø, ÆíµÎÅëÀ» ¾Î´ø ÇÑÀÇ»ç ÆíµÎÅëÀ» ¿ÏÄ¡ÇÏ´Ù 3 679 2023-05-19
944 â¿ø ¸¶»ê ´ß»ìÇǺΠ¸ð°ø°¢È­Áõ ÇÑÀÇ¿ø Ä¡·á·Î ½Î¾Ç~ 2 670 2023-05-11
943 ºÎ»ê¼­¸é´ÙÀ̾îÆ®ÇÑÀÇ¿ø »ýÈ°°Ç°­ÇÑÀÇ¿ø 5¿ù °¡Á¤ÀÇ´Þ Æ¯°¡À̺¥Æ® ½ÃÀÛ.. 3 895 2023-05-10
942 ±¸¿ùµ¿ÇÑÀÇ¿ø °æÈñÀÚ¶õÇÑÀÇ¿ø¿¡¼­ ´ÙÀ̾îÆ® ±³Åë»ç°í Ãß³ª¿ä¹ý ÀÎõ ³².. 2 819 2023-05-10
941 â¿ø´ÙÀ̾îÆ®ÇÑÀÇ¿ø, â¿ø´ÙÀ̾îƮȯ À¯¾Ø¹ÌÇÑÀÇ¿ø ½½¸²È¯ 2 807 2023-04-20
940 ûÁÖ º¹´ëµ¿ ÇÑÀÇ¿ø, ¸¶À½¿¡²ÉÇÑÀÇ¿ø º½¸ÂÀÌ À̺¥Æ® 18 898 2023-04-19
939 ¿µµîÆ÷ÇÑÀÇ¿ø ¼±ÇÑÀÇ¿ø Áñ°Å¿ö º½ À̺¥Æ® 14 792 2023-04-19
938 â¿ø ¸¶»ê ´ÙÀ̾îƮȯ À¯¾Ø¹ÌÇÑÀÇ¿ø 12 1,210 2023-03-20
937 â¿ø ¸¶»ê»êÈĺ¸¾à Çѹ泻°úÀü¹®ÀÇ °Ç°­ÇÑ È¸º¹ 14 992 2023-02-02
936 [¶óÀ²ÇÑÀÇ¿ø] º½À» ±â´Ù¸®´Â 2¿ù À̺¥Æ® 0 1,170 2023-02-02
935 ÇØ¿ÂÇÑÀÇ¿ø ¼³³¯À̺¥Æ® °øÁø´Ü °æ¿Á°í ½ÖÈ­ÅÁ ÇýÅà (~1/31) 1 913 2023-01-10
934 ÇÏÀÌÅ°ÇÑÀÇ¿ø 1¿ù À̺¥Æ® ¾È³» 0 1,069 2023-01-03
933 ¸¶ÀÌÇÃÇÑÀÇ¿ø ¿¬¸» °¨»ç À̺¥Æ® 0 1,430 2022-12-09
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷